52 percent AI, and 26 percent received neither. The percent receiving any endocrine therapy decreased with time from diagnosis. Among SERM and AI users, 20-30 percent were non-adherent to therapy; outof-pocket costs were higher for AI than SERM and were strongly associated with non-adherence. For AI users without a low income subsidy, adherence to therapy deteriorated after reaching the Part D coverage gap.
Introduction
Since January 2006, Medicare beneficiaries have had access to prescription drug benefits under the Part D program through enrollment in a Medicare Advantage prescription drug plan (MAPD) or a stand-alone drug plan (PDP). Under both plan types, the standard Part D benefit package includes an annual deductible ($250 in 2006) after which a 25-percent coinsurance rate applies up to an initial coverage limit ($2,250 in 2006) . After reaching the initial coverage limit, the enrollee enters a coverage gap (or "donut hole") during which he or she is responsible for 100 percent of all drug costs. If the enrollee reaches an out-of-pocket threshold ($3,600 in 2006) , catastrophic coverage begins with a five-percent coinsurance rate (Hoadley, 2006) . As an alternative to the standard Part D benefit, plans may elect to offer actuarially equivalent coverage or enhanced benefits with more comprehensive drug coverage. Some Part D plans with enhanced benefits provide them in the coverage gap, and they are often limited to generic drugs and sometimes also cover selected brand name drugs. Many plans offer different levels of coverage (referred to as tiers) within their formulary of covered drugs, with lower amounts of cost sharing usually associated with generics and preferred brand name drugs (Hoadley, Hargrave, Cubanski, & Newman, 2006) . Part D plans typically charge a monthly premium, which averaged $37 in PDPs and $18 in MAPDs in 2006 (Gold, 2006) . Beneficiaries with income and assets below specified levels, including those who are dually eligible for Medicare and Medicaid, may qualify to receive a low income subsidy (LIS), covering all or part of the Part D premium and most enrollee cost sharing, as well as costs in the coverage gap. Enrollment in Part D plans is voluntary; beneficiaries may continue to receive drug coverage from other sources in lieu of enrolling in a Part D plan or may choose to go without drug coverage. Dual eligibles are assigned to a PDP if they do not enroll in a plan voluntarily. As of January 2011, 28.4 million Medicare beneficiaries were enrolled in Part D plans (Centers for Medicare & Medicaid Services, 2011) .
There is substantial variation in the benefits offered by Part D plans; the variation in outof-pocket costs may influence beneficiary receipt of drug therapy (Goldman, Joyce, & Zheng, 2007; Maciejewski, Farley, Parker, & Wansink, 2010; Choudhry et al., 2010) . For non-LIS enrollees, cost-sharing prior to the coverage gap may include deductibles, fixed dollar copayments, coinsurance rates (i.e., a percentage of total costs), and classification of covered drugs into tiers with different levels of cost sharing. Most plans do not offer benefits in the coverage gap, although some offer coverage for lower tier drugs. Cost-sharing also varies for LIS enrollees, primarily related to income level and use of brand name vs. generic drugs.
Under Part D, Medicare covers adjuvant endocrine therapy, which has been shown to improve survival among women treated for breast cancer (Early Breast Cancer Trialists' Collaborative Group, 2005 ; The ATAC Trialists ' Group, 2002; Breast International Group [BIG] I-98 Collaborative Group, 2005) . Two classes of endocrine therapy medications are covered:
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selective estrogen receptor modulators (SERMs)-of which tamoxifen is the most commonly prescribed-and aromatase inhibitors (AIs). Tamoxifen has been widely prescribed since the 1970s and is available in generic form. Its use increased among breast cancer patients in the 1980s and 1990s (Harlan et al., 2006) . The first AIs were approved for use in the 1990s and are available as brand name drugs only. AI use has increased rapidly (Svahn et al., 2009; Aiello et al., 2008) and is displacing tamoxifen as the first course of endocrine therapy, following clinical trials that reported greater efficacy for AIs compared to tamoxifen (The ATAC Trialists ' Group, 2002; BIG I-98 Collaborative Group, 2005) . The National Comprehensive Cancer Network guidelines currently call for either SERMs or AIs to be provided to postmenopausal women with hormone receptor-positive breast cancer for a five year period following diagnosis (National Comprehensive Cancer Network, 2011) . To achieve the maximum benefit, patients must receive endocrine therapy for the full five years (Early Breast Cancer Trialists' Collaborative Group, 2005 The purpose of this study was to examine patterns of utilization and adherence to therapy, for SERM and AI, among elderly women diagnosed with hormone-receptor positive breast cancer and enrolled in a Medicare Part D prescription drug plan. Most previous studies have examined use of adjuvant endocrine therapy among elderly breast cancer patients prior to the introduction of Part D drug coverage, and many have been limited to smaller samples of patients or to specific health plans and providers (Svahn et al., 2009; Aiello et al., 2008; Lash, Fox, Westrup, Fink, & Silliman, 2006; Owusu et al., 2008; Hershman et al., 2010; Partridge, Wang, Winer, & Avorn, 2003) . This analysis adds to the literature by examining utilization patterns subsequent to the introduction of Part D coverage among a large and diverse sample of elderly breast cancer patients treated in a variety of clinical settings. A particular focus of the analysis is the relationship between medication adherence and variation in Part D benefits and cost sharing.
Data and Methods

Data
We used Surveillance, Epidemiology, and End Results (SEER) program cancer registry data, linked to Medicare administrative records (Warren, Klabunde, Schrag, Bach, & Riley, 2002) . The National Cancer Institute's SEER program contracts with fifteen population-based cancer registries to provide data on all incident cancer cases (with the exceptions of non-melanoma Riley, G., Warren J., Harlan L., Blackwell S.
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skin cancers and in situ cervical cancers) among residents of their reporting areas (Surveillance, Epidemiology, and End Results, 2010) . At the time of the study, the program covered 26 percent of the U.S. population. For each reported case, SEER receives data on patient demographics, cancer site, month and year of diagnosis, extent of disease at diagnosis, and initial course of therapy (including cancer-directed surgery and radiation therapy). Clinical data contained in SEER permitted the identification of cancer patients who were appropriate candidates for endocrine therapy, along with the specific five year recommended timeframe for that therapy for each patient.
The SEER-Medicare database contains Medicare enrollment and claims files, including prescription drug event (PDE) records. PDE records, derived from prescription drug claims, contain information on the covered drugs, fill dates, total costs, patient out-of-pocket costs, and days' supply. Each record also indicates the benefit phase in which the claim was estimated to occur (deductible, pre-coverage gap, coverage gap, and catastrophic phase) based on chronological order of the enrollee's claims, total and out-of-pocket costs, and plan coverage (Chronic Condition Data Warehouse, 2011) . PDE records are available for beneficiaries enrolled in both PDPs and MAPDs. . This guaranteed that our observation period fell within the recommended five year timeframe for endocrine therapy, but it also created a time lag between diagnosis and the beginning of our observation period for endocrine therapy use. We were not able to determine what percentage of patients initiated endocrine therapy or to calculate utilization and adherence rates immediately following diagnosis. Our analysis, therefore, effectively focused on the use of endocrine therapy after the initial course of cancer treatment, and specifically within an approximately two-year window of time that began up to three years after diagnosis. This permitted us to compare utilization and adherence to therapy at various points within the five-year timeframe for endocrine therapy.
Medicare calculates for each beneficiary a Hierarchical Condition Category (HCC) risk score, based on diagnostic and demographic factors predictive of future Medicare costs (Pope et al., 2004 To measure non-adherence to therapy, we identified the subset of sample members who had at least one PDE record for SERM or AI and who had at least 12 consecutive months of Part D enrollment following the first filled prescription for either drug. Non-adherence rates were computed separately for SERM and AI users, by LIS status; therefore, women who used both SERM and AI or who received the LIS for only part of the follow-up period, were excluded from the adherence analysis, yielding a final subset of 9,446 individuals. To calculate non-adherence rates, medication possession ratios (MPRs), consisting of total days' supply of the relevant drug divided by days of Part D enrollment, were computed for each case. The total days' supply was counted only up to the termination of Part D enrollment or December 31, 2007 (the end of the observation period). The denominator of the MPR was adjusted to remove days spent in a hospital or SNF. Consistent with common practice, cases with an MPR of less than 0.80 were defined as non-adherent (Kimmick et al., 2009; Partridge et al., 2003; Hershman et al., 2010) .
To measure the variation in drug benefits among plans, we examined out-of-pocket costs associated with SERM and AI prescriptions. Specifically, we calculated average out-of-pocket costs per 30 days' supply of SERM or AI for each beneficiary without LIS, based on prescriptions filled before the coverage gap was reached. This captured the variation in plan cost-sharing policies in the pre-coverage gap period. To measure the effect of any benefits in the coverage gap on adherence, we used plan-level files to identify whether benefits were available in the coverage gap, for the most frequently prescribed SERM or AI, for each non-LIS Part D enrollee. For LIS recipients average out-of-pocket costs per 30 days' supply were calculated based on all prescriptions filled, because these individuals do not experience a coverage gap.
The analysis of utilization patterns and adherence included descriptive statistics and cross-tabulations. Logistic regression was used to identify factors associated with lack of treatment with endocrine therapy between May 2006 and December 2007, and specifically to determine whether utilization decreased with time from diagnosis. Logistic regression was also used to identify demographic, clinical, and Part D coverage characteristics associated with nonadherence to SERMs and AIs among women who had initiated endocrine therapy. We did not include chemotherapy use among our covariates, because it is not captured in SEER and Riley, G., Warren J., Harlan L., Blackwell S.
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chemotherapy claims are not available for Medicare Advantage enrollees, who comprised a large portion of our sample. Analyses of non-adherence were stratified by LIS status after exploratory analyses revealed a strong interaction between LIS and out-of-pocket costs. Our primary analyses examined adherence among AI and SERM users separately, but we also pooled AI and SERM users (distinguishing them in the model with a binary variable) to compare nonadherence between the two drugs directly. All out-of-pocket costs incurred in 2006 were inflation-adjusted to 2007 dollars (Bureau of Labor Statistics, 2010).
A separate analysis was conducted of adherence to therapy during the coverage gap in 2007. From the 9,446 individuals identified for the adherence analysis, we selected enrollees without LIS who had at least one filled prescription for SERM or AI in the last quarter of 2006, who were enrolled in Part D for all of calendar year 2007, and who spent at least 30 days in the coverage gap in 2007. We then computed rates of non-adherence separately for time spent prior to the coverage gap and time spent in the coverage gap. Time spent in the catastrophic phase following the coverage gap was excluded from this analysis, because too few sample members had sufficient days in the catastrophic phase. LIS enrollees who incurred sufficient drug costs to reach the dollar threshold for the coverage gap, but who experienced no break in coverage, because of the LIS, were included in the analysis separately as a comparison. There were 5,436 individuals included in the analysis of adherence in the coverage gap.
Results
Utilization
During the period of May 2006-December 2007, 22 percent of beneficiaries received SERM, 52 percent received AI, and 26 percent received neither (Exhibit 1). Six percent of sample members received both SERM and AI and were classified in Exhibit 1 according to which drug they received first during the period of observation; among users of both drugs, 56 percent used SERM first and subsequently switched to AI (data not shown). Women diagnosed in 2005 were more likely to receive AIs during our observation period than women diagnosed in 2003 or 2004, consistent with reported trends toward greater use of AI among more recently diagnosed cases (Svahn et al., 2009; Aiello et al., 2008) . 
Percent using drug
Adherence
Among SERM users 21 percent of non-LIS recipients and 24 percent of LIS recipients were nonadherent to therapy (Exhibit 3). Among AI users 30 percent of non-LIS recipients and 20 percent of LIS recipients were non-adherent. Adherence did not vary significantly with year of diagnosis, given some use of endocrine therapy in the observation period. Non-adherence increased significantly with increasing out-of-pocket costs for both LIS and non-LIS recipients, among both SERM and AI users. For example, among AI users without LIS, 10 percent of those with less than $5 in out-of-pocket costs per 30 days' supply were non-adherent, compared to 33 percent of those with $15 or more in out-of-pocket costs. Out-of-pocket costs varied less among LIS recipients than among non-LIS recipients, but adherence was still significantly better among those with lower out-of-pocket costs, among both SERM and AI users.
Logistic regression analysis confirmed the relationship between adherence and out-ofpocket costs, especially among non-LIS recipients (Exhibit 4). Among SERM users without LIS, the OR for non-adherence was 3.31 (95 percent CI = [2.14, 5.12]) for those with $15 or more in Excludes 12 SERM and 57 AI cases with no pre-coverage gap claims. 4 Includes unknown radiation therapy status.
5
Includes 22 cases with out-of-pocket costs of $30+.
6
Includes 11 cases with out-of-pocket costs of $5+. Notes:
• SERM = selective estrogen receptor modulator; AI = aromatase inhibitor; BCS=breast conserving surgery; MAPD=Medicare Advantage prescription drug plan; PDP=stand-alone prescription drug plan; HCC= Hierarchical Condition Category.
• Table includes • Non-adherence is defined as a medication possession ratio of less than 80 percent. Source: SEER-Medicare.
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3
Includes 11 cases with out-of-pocket costs of $5+. 4 Includes unknown radiation therapy status. Notes:
• SERM = selective estrogen receptor modulator; AI = aromatase inhibitor; BCS=breast conserving surgery; MAPD=Medicare Advantage prescription drug plan; PDP=stand-alone prescription drug plan; CI=confidence interval; HCC=Hierarchical Condition Category.
• Table includes • Cases with both AI and SERM were excluded from this analysis.
• The models exclude 12 SERM and 57 AI non-low income subsidy cases with no pre-coverage gap claims.
• Non-adherence is defined as a medication possession ratio of less than 80 percent.
• The model also includes variables for each SEER registry (data not shown in table). Source: SEER-Medicare.
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out-of-pocket costs per 30 days' supply compared to those with less than $5 in out-of-pocket costs. The comparable OR for AI users was 4.52 (95 percent CI = [3. 05, 6 .69]). The relationship between adherence and out-of-pocket costs was not as strong for LIS recipients. Among AI users without LIS, adherence was significantly better for those with benefits in the coverage gap for their most frequently prescribed AI (OR for non-adherence = 0.60, 95 percent CI = [0.37, 0.97]). Adherence was poorer among black beneficiaries without LIS for both SERM and AI. High risk scores were associated with poorer adherence for SERM users without LIS and for AI users with LIS.
The strong relationship between out-of-pocket costs and adherence suggests that the poorer adherence associated with AI users without LIS may be attributable to the higher cost of AI to the beneficiary. After pooling SERM and AI users without LIS, AI users were shown to be more likely to be non-adherent, controlling for demographic, health status, and cancer-related factors (OR = 1.67, 95 percent CI = [1.47, 1.90]; data not shown). After further adjusting for outof-pocket costs and the presence of benefits in the coverage gap, AI users were less likely to be non-adherent (OR = 0.63, 95 percent CI = [0.51, 0.78] ).
Adherence deteriorated among AI users who entered the coverage gap (Exhbit 5). Among AI users without LIS, 13.4 percent were non-adherent prior to the coverage gap, with 25.3 percent non-adherent during time spent in the coverage gap. SERM users without LIS experienced non-significantly poorer adherence after entering the coverage gap. By comparison, LIS recipients, who suffered no break in coverage, experienced a small non-significant improvement in adherence after the coverage gap threshold was reached.
Discussion
Our findings present a mixed view of utilization and adherence patterns for AI and SERM under Part D. Although most women were receiving some endocrine therapy during the 20 months of our study, a significant minority were not. Among those receiving therapy, a substantial number was non-adherent, especially among AI users. Higher out-of-pocket costs were strongly associated with non-adherence to therapy for both AI and SERM users, and among both LIS and non-LIS recipients. We also observed a significant deterioration in adherence during the coverage gap among AI users.
Of the elderly women with Part D coverage who had hormone receptor-positive breast cancer, 26 percent were not receiving SERM or AI therapy between one and five years after diagnosis, a period when endocrine therapy is recommended for all patients. As time from diagnosis increased, use of endocrine therapy decreased. A prior study of a sample of SEER cases diagnosed in 2000 found approximately 28 percent of women with ER-positive breast cancers did not receive tamoxifen as part of initial therapy (Harlan, Clegg, Abrams, Stevens, & BallardBarbash, 2006) . Studies based on other populations have found that 20-50 percent of SERM and AI users fill too few prescriptions to provide an adequate days' supply of their drug or they Riley, G., Warren J., Harlan L., Blackwell S.
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discontinue therapy early, with lack of treatment tending to increase with time from diagnosis (Partridge et al., 2003; Owusu et al., 2008; Lash et al., 2006; Chlebowski & Geller, 2006; Hershman et al., 2010; Partridge et al., 2008) . Reasons for lack of treatment include side effects, patient attitudes and beliefs, duration of therapy, out-of-pocket costs, and patient experiences Enrollees incurred sufficient drug costs to reach the coverage gap but continued to receive Part D benefits thereafter under the low income subsidy. Notes:
• SERM=selective estrogen receptor modulator; AI=aromatase inhibitor.
• Table includes • Excludes enrollees with less than 30 days in the coverage gap.
• Cases with both AI and SERM use were excluded from this analysis. Source: SEER-Medicare.
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with care (Kahn, Schneider, Malin, Adams, & Epstein, 2007; Chlebowski & Geller, 2006; Hadji, 2010) . Despite the variation in Part D benefits and the presence of a coverage gap for most enrollees, utilization of endocrine therapy under Part D appears comparable to utilization rates observed in other settings.
We found significantly lower medication adherence among enrollees who experienced higher out-of-pocket costs, especially among AI users. This suggests that differences in plan cost sharing have important implications for enrollee access to essential medications. Other research has indicated that most beneficiaries do not select Part D plans that minimize their out-ofpocket costs for their medications (Gruber, 2009; Patel et al., 2009 ). Many have a poor understanding of the Part D program and most do not compare plan cost and benefits in theirenrollment decisions (Hibbard, Greene, & Tusler, 2006) . Enrollees are also reluctant to switch plans, even if it would improve their benefits (Polinski, Bhandari, Saya, Schneeweiss, & Shrank, 2010) . In particular, LIS recipients, many of whom are initially randomly assigned to selected plans, may improve access by switching to more appropriate plans (United States Government Accountability Office, 2007).
We found evidence that the Part D coverage gap may adversely affect adherence among AI users without LIS. Adherence was significantly better for AI users who had some coverage for their AI drug during the coverage gap phase, although the same did not hold true for SERM users. In addition, adherence deteriorated significantly among AI users after the coverage gap was reached. The effect of the coverage gap on adherence may be understated in our data if some enrollees discontinue therapy before entering the coverage gap, in anticipation of encountering much higher out-of-pocket costs. Any effect of the coverage gap on adherence may be mitigated over time as the coverage gap is phased out of the Part D program (Centers for Medicare & Medicaid Services, 2010).
Among women receiving endocrine therapy, we found higher rates of non-adherence among AI users than among SERM users for beneficiaries without LIS. Previous studies based on clinical trials and observational data have found non-adherence rates to be similar for these two classes of drugs (Chlebowski & Geller, 2006; Hershman et al., 2010) . Our findings suggest the poorer adherence among AI users that we observed may be attributable to the higher out-ofpocket costs associated with that class of drugs under Part D. Large differences in out-of-pocket costs between SERMs and AIs result in part from the structure of the standard Part D benefit, which imposes a deductible, a 25 percent coinsurance rate, and a coverage gap during which patients are responsible for the full cost of their drugs. Most Part D plans that provided benefits in the coverage gap in years 2006-2007 did so only for generic drugs (Hargrave, Hoadley, Cubanski, & Neuman, 2009) , providing little relief for AI users. The utilization restrictions placed on higher tier drugs (e.g., quantity limits, prior authorization) may also affect adherence for AI users. If AIs continue to displace SERMs as they have in recent years, adherence to endocrine therapy could worsen over time among beneficiaries without LIS.
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Dually eligible beneficiaries (individuals with both Medicare and Medicaid coverage) have historically received drug coverage through the Medicaid program, but under Part D most of their drug coverage is now provided by Medicare. Previous studies have found substantial rates of non-adherence to endocrine therapy among Medicaid recipients with breast cancer (Kimmick et al., 2009; Partridge et al., 2003) . Concerns have been expressed that the transition to Medicare drug coverage may have created financial barriers to the receipt of needed medications for many dual eligibles through greater cost sharing or formulary restrictions (Elliott, Majumdar, Gillick, & Soumerai, 2005) . Although we could not observe drug utilization patterns of dual eligibles prior to coverage under Part D, we did compare utilization and adherence rates for endocrine therapy between LIS recipients (who are comprised mostly of dual eligibles) and non-LIS recipients under Part D. Similar percentages of LIS and non-LIS enrollees received endocrine therapy and similar percentages received AIs, which are more expensive than SERMs. Moreover, among AI users adherence rates were significantly higher for LIS recipients than for non-LIS recipients. Access to endocrine therapy, therefore, appears to be as good for dual eligibles as for other beneficiaries. Our findings are consistent with other studies that have found few problems with the transition of drug coverage for dual eligibles from Medicaid to Part D (Polinski, Kilabuk, Schneeweiss, Brennan, & Shrank, 2010) .
Several limitations of this study should be noted. First, we could not observe SERM and AI use from time of diagnosis, when endocrine therapy is recommended to commence. However, our study included an interval when all patients should have been receiving endocrine therapy. Second, our analyses of factors related to utilization and adherence could not account for side effects, which are an important reason for non-adherence and discontinuation of these drugs (Chlebowski & Geller, 2006) . Third, our sample was limited to Part D enrollees, who tend to be less healthy and have lower incomes than non-Part D enrollees (Riley, Levy, & Montgomery, 2009) . Fourth, some of our findings could be explained by biased selection of beneficiaries into plans with different cost sharing and benefit packages (Riley, et. al, 2009) . That is, beneficiaries who make the effort to enroll in plans that minimize cost-sharing for endocrine therapy drugs may also tend to be more meticulous about remaining adherent to therapy. Lastly, we could not be certain that our database captured all prescription fills for our sample. For example, some beneficiaries may obtain free sample medications from their doctors or receive their drugs through other sources that would not show up in PDE records, particularly during the coverage gap. Despite the study limitations, this analysis represents the first use of Medicare Part D records incorporated into the SEER-Medicare database, demonstrating the potential value of the data for studying prescription drug use among elderly cancer patients.
We conclude that under Part D, most elderly women with breast cancer who could benefit from endocrine therapy are receiving recommended treatment. However, a sizeable proportion is not receiving endocrine therapy in the recommended time frame following their diagnosis. In addition, among those women initiating endocrine therapy, about one-quarter was non-adherent, with out-of-pocket costs appearing to be a significant factor. Failure to initiate
